The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).
Ashley Knight-Greenfield
No relevant relationships to disclose
Richard Aaron Marshall
No relevant relationships to disclose
Martin Hutchings
No relevant relationships to disclose
John Doucette
No relevant relationships to disclose
Jamie Stern
No relevant relationships to disclose
Morton Coleman
No relevant relationships to disclose
Lale Kostakoglu
No relevant relationships to disclose